- Home
- OTLK vs ADAG Comparison
OTLK vs ADAG Comparison
Compare OTLK & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | ADAG |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | China |
| Employees | 17 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 84.8M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OTLK | ADAG |
|---|---|---|
| Price | $0.56 | $1.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 8.1M | 49.9K |
| Earning Date | 02-13-2026 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,413,535.00 | $103,204.00 |
| Revenue This Year | $2,048.59 | $6,983.06 |
| Revenue Next Year | $142.11 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $1.30 |
| 52 Week High | $3.39 | $3.16 |
Technical Indicators
Market Signals| Indicator | OTLK | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 22.80 | 45.78 |
| Support Level | $1.78 | $1.74 |
| Resistance Level | $2.03 | $1.90 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 2.64 | 53.12 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.